Internal applications for fibrin glues in surgical procedures including cardiac, vascular and thoracic surgery account for the majority of sealant usage. General surgery, neurosurgery, plastic, ear, nose and throat, wound management, urology, and orthopedics are the other major uses of the products today. The majority of fibrin glue products and sealant products were first used for internal surgical hemostasis and sealant effects. This is now changing with the realization that appropriate hemostasis and gluing of surgical wounds during closure results in reduced infection rates and better cosmesis. Growth rates in the synthetic and biological adhesives segment of the surgical closure market will be more modest than in the high-strength segment of the market, since these technologies have most potential in niche opportunities, competing with established use of autologous and allogeneic fibrin products from a number of major established players (e.g., Baxter) and a number of new device suppliers such as PlasmaSeal and Harvest Medical, as well as future recombinant human fibrin producers such as Protein Polymer Therapeutics.
In the MedMarket Diligence report #S175, shares of the fibrin and sealant market, worldwide, are detailed for this market, which is growing at over 13% annually. Seven companie command 92% of the market, encompassing the fibrin/sealant revenues of CSL Behring, Kaketsuken, Baxter, CryoLife, Haemacure, Harvest Technologies and Interpore Cross (Biomet). A growing number of players are penetrating the market, seeking to wrest greater share from, in particular, the top three players, CSL Behring, Kaketsuken and Baxter.